|
|
||||||||
Published online before print February 25, 2008
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



* Centro Ricerche Biotecnologie Innovative and
Istituto Veneto Medicina Molecolare, Dipartimento di Scienze Biomediche Sperimentali, Università di Padova, Padova, Italy;
Rzeszów University of Technology, Faculty of Chemistry, Department of Biochemistry and Biotechnology, Rzeszów, Poland; and
Research Centre, Novartis Vaccines and Diagnostics S.r.l., Siena, Italy
1Correspondence: C.R.I.B.I.-University of Padova, Via G. Colombo 3, 35121 Padova, Italy. E-mail: emanuele.papini{at}unipd.it
ABSTRACT
Specific surface proteins of Neisseria meningitidis have been proposed to stimulate leukocytes during tissue invasion and septic shock. In this study, we demonstrate that the adhesin N. meningitidis Adhesin A (NadA) involved in the colonization of the respiratory epithelium by hypervirulent N. meningitidis B strains also binds to and activates human monocytes/macrophages. Expression of NadA on the surface on Escherichia coli does not increase bacterial-monocyte association, but a NadA-positive strain induced a significantly higher amount of TNF-
and IL-8 compared with the parental NadA-negative strain, suggesting that NadA has an intrinsic stimulatory action on these cells. Consistently, highly pure, soluble NadA
351–405, a proposed component of an antimeningococcal vaccine, efficiently stimulates monocytes/macrophages to secrete a selected pattern of cytokines and chemotactic factors characterized by high levels of IL-8, IL-6, MCP-1, and MIP-1
and low levels of the main vasoactive mediators TNF-
and IL-1. NadA
351–405 also inhibited monocyte apoptosis and determined its differentiation into a macrophage-like phenotype.
Key Words: adhesion molecule bacterial infection inflammation cytokines chemokines
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |